Australia - englanti - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - potassium chloride -

Australia - englanti - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - water for injections -

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - propranolol hydrochloride -

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - propranolol hydrochloride -

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - felodipine -

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - felodipine -

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - felodipine -

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

astrazeneca sdn. bhd. - atenolol -

Yhdysvallat - englanti - NLM (National Library of Medicine)

astrazeneca pharmaceuticals lp - azd-1222 (unii: b5s3k2v0g8) (azd-1222 - unii:b5s3k2v0g8) -

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

astrazeneca limited - fulvestrant 50 mg/ml;   - solution for injection - 250 mg/5ml - active: fulvestrant 50 mg/ml   excipient: benzyl alcohol benzyl benzoate castor oil ethanol - faslodex is indicated for the treatment of locally advanced or metastatic breast cancer in postmenopausal women of any age: - not previously treated with endocrine therapy, or - previously treated with endocrine therapy (antioestrogen or aromatase inhibitor) therapy, irrespective of whether their postmenopausal status occurred naturally or was artificially induced.